
Human Cytochrome P450 1B1 190-198, FLDPRPLTV
Description
About Human Cytochrome P450 1B1 190-198, FLDPRPLTV
The Human Cytochrome P450 1B1 Peptide (IEDB: 193756) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Cytochrome Peptide, H-FLDPRPLTV-OH (Uniprot: Q16678 aa: 190-198) from JPT is produced under strict quality control and quality management.
Human Cytochrome P450 1B1 190-198, FLDPRPLTV - Specifications
- Peptide sequence: H-FLDPRPLTV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Breast cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Cytochrome P450 1B1 190-198, FLDPRPLTV
References:
Read References with JPT’s Antigen Peptides
Human Cytochrome P450 1B1 190-198, FLDPRPLTV has been described in:
Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL., J Immunol, 2012 (PMID: 22544926)
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)., Proc Natl Acad Sci U S A, 2015 (PMID: 25548167)
Documentation
Documentation for Human Cytochrome P450 1B1 190-198, FLDPRPLTV
Properties
Properties of Human Cytochrome P450 1B1 190-198, FLDPRPLTV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Cytochrome |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Cytochrome P450 1B1 190-198, FLDPRPLTV
Information | Values |
---|---|
Sequence: | H-FLDPRPLTV-OH |
Specifications: | 9mer peptide as TFA salt |